Skip to content

Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment …

Published by chris24 on January 10, 2022
Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment …

Idorsia Ltd (SIX: IDIA) today announced that the US Food and Drug Administration (FDA) has approved QUVIVIQ™ (daridorexant) 25 mg and 50 mg for …
See all stories on this topic

Mental Illness Drugs Market Research Report: Latest Industry Status and Future Growth …

South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, …
See all stories on this topic

Patient Engagement Technology Market: Increasing focus on patients for providing … – BioSpace

With respect to the regional growth, North America stands out and … Substance abuse, tobacco, alcohol, and drug addiction are on the rise at the …
See all stories on this topic

Substance Abuse Treatment Market Report Provides In-Depth Analysis, IndEuropetry Share …

Regional Substance Abuse Treatment Market (Regional Output, Demand & Forecast by Countries):- North America (United States, Canada, Mexico) South …
See all stories on this topic

Behavioral Therapy Market Report, History and Forecast 2015-2026, Breakdown Data by …

Regional bifurcation: North America, Europe, Asia-Pacific, South America … Product types: Anxiety Disorders , Mood Disorders , Substance Abuse …
See all stories on this topic

Published inSubstance Abuse

Be First to Comment

Leave a Reply